NCT05618314

Study of AT-527 in Subjects With Normal and Impaired Renal Function

A Phase 1, Open-Label, Parallel-Group, Single-Dose Adaptive Study to Evaluate the Safety and Pharmacokinetics of AT-527 in Adult Subjects With Normal and Impaired Renal Function Sub-Study: Effects of Probenecid on the Pharmacokinetics of AT-527 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Study of AT-527 in Subjects with Normal and Impaired Renal Function

Conditions

• Healthy Volunteer
• Renal Impairment

Interventions

Type	Name	Description
DRUG	AT-527	single dose AT-527
DRUG	AT-527	Single dose of AT-527 pre- and post-dialysis
DRUG	AT-527 and Probenecid	Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19

Timeline

• Start date: 2022-10-17
• Primary completion: 2024-06-15
• Completion: 2024-06-15
• First posted: 2022-11-16
• Last updated: 2024-07-31

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study